Senior Management

Expand all CVs×Hide all CVs

Dr. Heinz Schwer

Chief Executive Officer

More about:
Dr. Heinz Schwer

CV

Dr. Schwer served three years as CEO of Lanthio Pharma B.V., a Dutch drug development company that was acquired by MorphoSys AG. He led the company’s effort in advancing its therapeutic program from pre-clinical into clinical stage. Before his time at Lanthio, Dr. Schwer was Senior Director at MorphoSys AG from 2010 until 2014. In this period he served as strategic technology advisor and head of “Innovation Capital”, the company’s corporate venture business. Prior to this position, he was co-founder and CEO of Sloning Biotechnology, a biotech company that became market leader in generating recombinant gene libraries for pharma and industrial biotech. Throughout his career, Dr. Schwer has been involved in numerous M&A transactions and helped to raise over EUR 40m capital through private and public offerings. Dr. Schwer received his PhD in clinical chemistry from University of Regensburg, was a postdoctoral fellow at Harvard Medical School at the Beth Israel Hospital and Dana-Faber Cancer Institute and holds an MBA from Henley Management College, UK.

×Show less

Dr. Lisa Egerer

Chief Operating Officer

More about:
Dr. Lisa Egerer

CV

Dr. Lisa Egerer comes to ViraTherapeutics from the Medical University of Innsbruck where she was a principle scientist and lab manager at the Division of Virology and helped provide the basis for founding of ViraTherapeutics as a spin-out company. Prior to that she trained in applied virology and gene therapy at the Institute for Biomedical Research Georg-Speyer-Haus in Frankfurt, Germany. Dr. Egerer obtained a PhD and a degree in Biochemistry from Goethe University Frankfurt, Germany, and holds a degree in intellectual property law from Beuth University of Applied Sciences Berlin, Germany. In her role as Chief Operating Officer at ViraTherapeutics, Dr. Egerer oversees operations and is in charge of finance and controlling, public funding, human resources, intellectual property and quality management.

×Show less

PD Dr. Dethardt Müller

Head of CMC

More about:
PD Dr. Dethardt Müller

CV

Dr. Müller joined ViraTherapeutics GmbH as Head of CMC in July 2016 from Rentschler Biotechnologie GmbH, where he served over seven years as Head of Process Science and Technology. In this function he was responsible for the development and implementation of innovative process technologies and platforms used in biopharmaceutical manufacturing of therapeutic proteins in mammalian cells. He has overseen main projects in the field of recombinant cell line development using targeted integration, single-use process technologies with regard to leachable/extractable impact on process performance and safety, and in the conception of Quality by Design compliant bioprocessing using multivariate methods for process design, analysis and control. Dr. Müller gained in-depth expertise in biopharmaceutical process engineering as Assistant Professor at BOKU University in Vienna where he received his PhD in Biotechnology and his Habilitation in Bioprocess Engineering.

×Show less

Dr. Patrik Erlmann

Head of R&D

More about:
Dr. Patrik Erlmann

CV

Before joining ViraTherapeutics first as R&D Scientist and Senior Scientist in the Assay Development Dr. Erlmann worked as postdoctoral fellow and DFG stipendiate in the Laboratory of Prof. Malhotra (CRG, Barcelona) investigating the secretory pathway of proteins. Dr. Erlmann studied biochemistry with a focus on virology at the University of Tübingen and the Friedrich-Löffler-Institut in Tübingen he then received his PhD in Molecular Oncology from Stuttgart University (summa cum laude).

×Show less

Dr. Cédric Cheminay

Project Manager Preclinical Development
Deputy Head of R&D

More about:
Dr. Cédric Cheminay

CV

Dr. Cédric Cheminay obtained a PhD in Immunology at the Friedrich-Alexander-University of Erlangen-Nürnberg, Germany. During his academic career at the Pasteur Institute of Lille, FAU and Ludwig-Maximilian-University, he focused his research on the interactions of pathogens, bacteria and different vaccine platforms with the immune system, especially dendritic cells. In 2007, he joined Bavarian Nordic and participated in research activities and preclinical development of MVA-BN and several poxvirus-based vaccines (e.g. RSV, HIV, Filoviruses). Since 2016, he is responsible of the VSV-GP pre-clinical development program at ViraTherapeutics.

×Show less